个体化治疗时代多靶点药物究竟何去何从——多靶点药物治疗非小细胞肺癌最新临床进展综述

Current Status and Future Direction of Multi-targeted Drugs in the Era of Personalized Therapy —Overview of Advances in Multi-targeted Therapy in Non-small Cell Lung Cancer

目前在非小细胞肺癌治疗中,多靶点药物占有举足轻重的地位。近年来随着多项III期临床结果的陆续公布,多靶点药物的疗效可谓喜忧参半。在个体化治疗的大方向下,如何发挥多靶点药物的最佳疗效,的确值得我们探索。本文综述了近年来多靶点药物治疗非小细胞肺癌的最新临床进展,希望能有所启发。

Multi-targeted tyrosine kinase inhibitors （TKIs） play important roles in the treatment of non-small cell lung cancer （NSCLC）. Recently, results of several large phase III studies have been published, showing bittersweet the cacy of multi-targeted TKIs. In the era of personalized therapy, optimal use of multi-targeted TKIs is worthy of further investigation. In this review, we summarized current clinical development and future direction of multi-targeted TKIs in NSCLC..